2023
Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited States
2012
Understanding Reduced Rotavirus Vaccine Efficacy in Low Socio-Economic Settings
Lopman BA, Pitzer VE, Sarkar R, Gladstone B, Patel M, Glasser J, Gambhir M, Atchison C, Grenfell BT, Edmunds WJ, Kang G, Parashar UD. Understanding Reduced Rotavirus Vaccine Efficacy in Low Socio-Economic Settings. PLOS ONE 2012, 7: e41720. PMID: 22879893, PMCID: PMC3412858, DOI: 10.1371/journal.pone.0041720.Peer-Reviewed Original ResearchConceptsLow socio-economic settingRotavirus vaccine efficacyVaccine efficacyRotavirus vaccineSevere diseaseNatural infectionImmunogenicity of vaccinationReduced vaccine efficacySevere rotavirus gastroenteritisReduced efficacyClinical trial resultsLow SES populationsRotavirus gastroenteritisVaccine performanceVaccination programImmune responseEpidemiological factorsVaccineVaccinationTrial resultsInfectionSES populationsEfficacyReduced protectionEfficacy declines